Arbutus Biopharma
ABUS
172 hedge funds and large institutions have $587M invested in Arbutus Biopharma in 2025 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 55 increasing their positions, 45 reducing their positions, and 15 closing their positions.
200% more call options, than puts
Call options by funds: $14.3M | Put options by funds: $4.77M
47% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 15
22% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 45
9% more capital invested
Capital invested by funds: $536M → $587M (+$50.5M)
4% more funds holding
Funds holding: 166 → 172 (+6)
1.8% more ownership
Funds ownership: 61.64% → 63.45% (+1.8%)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$11.3M |
| 2 |
Morgan Stanley
New York
|
+$10.1M |
| 3 |
State Street
Boston,
Massachusetts
|
+$8.14M |
| 4 |
TSC
Two Seas Capital
Rye,
New York
|
+$7.19M |
| 5 |
UBS AM
Chicago,
Illinois
|
+$4.01M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FC
Foursixthree Capital
New York
|
-$8.98M |
| 2 |
Goldman Sachs
New York
|
-$6.45M |
| 3 |
FCM
FourWorld Capital Management
New York
|
-$4.63M |
| 4 |
Aberdeen Group
Edinburgh,
United Kingdom
|
-$3.63M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$3.04M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
176
Millennium Management
New York
| – | -$2.4M | -528,340 | Closed |
|
|
YIH
177
Y-Intercept (HK)
Hong Kong
| – | -$300K | -66,056 | Closed |
|
178
Assenagon Asset Management
Senningerberg,
Luxembourg
| – | -$121K | -26,702 | Closed |
|
|
JG
179
Jain Global
New York
| – | -$118K | -26,000 | Closed |
|
|
OAC
180
OMERS Administration Corp
Toronto,
Ontario, Canada
| – | -$98.5K | -21,700 | Closed |
|
181
Prudential Financial
Newark,
New Jersey
| – | -$82.9K | -18,255 | Closed |
|
|
GCM
182
Graham Capital Management
Rowayton,
Connecticut
| – | -$60.2K | -13,265 | Closed |
|
183
Principal Financial Group
Des Moines,
Iowa
| – | -$53.8K | -11,859 | Closed |
|
|
TSS
184
Two Sigma Securities
New York
| – | -$52.4K | -11,534 | Closed |
|
|
XT
185
XTX Topco
George Town,
Cayman Islands
| – | -$51.6K | -11,364 | Closed |
|
|
NA
186
NewEdge Advisors
New Orleans,
Louisiana
| – | -$2.27K | -500 | Closed |
|
|
PS
187
Principal Securities
Des Moines,
Iowa
| – | -$1.04K | -230 | Closed |
|
ABUS Hedge Fund Activity: Q4 2025 in Review
172 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q4 2025, worth a combined $587M — up 9.4% from $536M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new ABUS positions and 15 closed out — a net gain of 7 holders — while 55 added to existing stakes and 45 trimmed.
The largest buyer was ADAR1 Capital Management, adding an estimated $11.3M. The largest seller was Foursixthree Capital, exiting entirely with an estimated $8.98M sold.
- 172 institutional investors held Arbutus Biopharma (ABUS) as of Q4 2025, up from 166 in Q3 2025.
- Funds reported $587M of Arbutus Biopharma stock for Q4 2025, up 9.4% quarter-over-quarter.
- 22 funds opened new Arbutus Biopharma positions in Q4 2025 and 15 closed out, a net change of +7 holders.
- The largest Arbutus Biopharma buyer in Q4 2025 was ADAR1 Capital Management, an estimated $11.3M added.
- The largest Arbutus Biopharma seller in Q4 2025 was Foursixthree Capital, an estimated $8.98M sold.
Based on aggregated 13F filings for Q4 2025.